TAI

PROCEDURE3 trials

Sponsors

Sun Yat-sen University

Conditions

Hepatocellular Carcinoma

Phase 3

The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2017-07-01End: 2024-12-31Target: 162Updated: 2017-06-20

The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

RecruitingNCT03368651

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2016-01-01End: 2028-12-31Target: 230Updated: 2017-12-11

The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2018-07-01End: 2024-08-31Target: 344Updated: 2019-11-29

Related Papers

Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial.

Journal of Clinical Oncology2023-06-0111 citations

Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.

Journal of Clinical Oncology2021-05-2029 citations